The animal study, led by Matthias Tschöp, MD, professor in the University of Cincinnati (UC) endocrinology division, appears online ahead of print Sunday, June 6, 2010, in Nature Neuroscience.
“We have long thought that cholesterol is exclusively regulated through dietary absorption or synthesis and secretion by the liver,” says Tschöp. “Our study shows for the first time that cholesterol is also under direct ‘remote control’ by specific neurocircuitry in the central nervous system.”
The hormone ghrelin inhibits the melanocortin 4 receptor (MC4R) in the hypothalamus and is important for the regulation of food intake and energy expenditure. Tschöp and his team found that increased levels of ghrelin in mice caused the animals to develop increased levels of blood-circulating cholesterol. This, the authors say, is due to a reduction in the uptake of cholesterol by the liver.
The research team next tested the effects of genetically deleting or chemically blocking MC4R in the central nervous system. This test also yielded increased levels of cholesterol, suggesting that MC4R was the central element of the “remote control.”
“We were stunned to see that by switching MC4R off in the brain, we could even make injected cholesterol remain in the blood much longer,” says Tschöp, a researcher at UC’s Metabolic Diseases Institute.
Cholesterol is a type of naturally occurring fat needed by the body, but too much cholesterol can lead to atherosclerosis, a buildup of plaque in the arteries. There are two types of cholesterol in humans―HDL (high-density lipoprotein) and LDL (low-density lipoprotein). LDL is considered the “bad” kind of cholesterol responsible for plaque buildup. HDL is the “good” kind that, in high levels, can prevent atherosclerosis.
Atherosclerosis can lead to heart attack. The American Heart Association estimates that a heart attack occurs every 34 seconds in the United States.
Due to the differences in the make-up of mice and human cholesterol, Tschöp and his team say more work is needed before their studies could be directly applied to humans, but they say their finding adds to a growing body of evidence for the central nervous system’s direct control over essential metabolic processes.
This study was supported by a grant from the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases and individual investigator awards from the American Heart Association and the American Diabetes Association.
Co-authors include Stephen Benoit, Joshua Bashford, William Davidson, Norm Granholm, Erin Grant, Susanna Hofmann, David Hui, Ruben Nogueiras, Diego Perez-Tilve, Paul Pfluger, Hilary Wilson-Perez and Stephen Woods, all from the University of Cincinnati; Myrtha Arnold from the Institute of Animal Science in Schwerzenbach, Switzerland; Andrew Butler and James Trevaskis from Pennington Biomedical Research Center in Louisiana; James Patterson and Mark Sleeman from Regeneron Pharmaceuticals; and Richard DiMarchi from Indiana University.
UC’s Metabolic Diseases Institute, named in 2009, is located on UC’s Reading Campus, formerly the Genome Research Institute, and is home to a team of researchers who focus on the genetic, molecular and cellular mechanisms of metabolic disorders, cancer and cardiovascular disease.
Media Contact: Dama Kimmon, (513) 558-4519